SENORES

Current scenario - Reported highest-ever quarterly revenue of INR192 crores (up 25% YoY) and EBITDA of INR58 crores (up 38% YoY) for Q2 FY27. - Regulated market business grew 28% YoY driven by portfolio expansion and distribution channels; ANDA portfolio increased to 64 with 23 commercialized. - Apnar facility operating at high capacity with validation works; fourth commercial line expected by March 2027. Changes in trends - Transitioning branded generics in India from volume-focused to margin-focused with gross margins improving significantly from 18%-20% to over 60%. - Emerging market margins slightly declined due to large beta-lactam orders but expected to normalize to mid-teens. Management Guidance & Outlook - Maintained FY27 guidance of 30%-40% revenue growth and 50%-60% PAT growth, backed by upcoming product launches and contributions from subsidiaries Amerisyn and Zoraya. - Expecting sustained annual growth of around 25% over the next 2-3 years. Capex - H1 FY27 capex stood at approximately INR46 crores, focused on capacity expansions and technology upgrades like SAP HANA. Growth Drivers - Ramp-up of new ANDA/sANDA approvals, controlled substance launches, GLP-1 peptide portfolio for emerging markets, and commercialization of recent subsidiaries Amerisyn and Zoraya in H2 FY27.

- Senores Pharmaceuticals Limited informed the stock exchanges about the audio recording link of the earnings conference call for Q2 & H1 FY27 held on October 29, 2026. - The audio recording is made available on the company website at https://senorespharma.com/investor-meet/.

Q2 FY27 Consolidated Revenue ₹192.3Cr vs ₹153.9Cr (▲25% YoY) EBITDA ₹57.7Cr vs ₹41.7Cr (▲38.3% YoY) PAT ₹36.6Cr vs ₹30.1Cr (▲21.6% YoY) EBITDA Margin 30% vs 27.1% (▲290bps)

Q2 FY27 Consolidated Revenue ₹192.33Cr vs ₹153.94Cr (▲25% YoY) EBITDA ₹57.66Cr vs ₹41.69Cr (▲38% YoY) PAT ₹36.60Cr vs ₹30.12Cr (▲22% YoY) EBITDA Margin 29.98% vs 27.08% (▲290bps) - Approved appointment of M/s Talati and Talati LLP as Joint Statutory Auditors alongside existing auditors M/s Pankaj R Shah & Associates for FY 2026-27 to FY 2030-31.

- Q2 FY27 Revenue grew 25% YoY to ₹192 Cr; EBITDA rose 38% YoY to ₹58 Cr. - Q2 FY27 PAT increased 22% YoY to ₹37 Cr. - FY27 Guidance: On track to deliver 30–40% revenue growth and 50–60% PAT growth. - Regulated markets portfolio expanded to 64 ANDAs with 23 commercialized.

- Senores Pharmaceuticals announced capacity expansion plans across multiple subsidiaries. - Havix Group INC (USA) capacity to increase from 1.2 Bn to 2.0 Bn units at an estimated cost of ₹18.00 Cr. - Apnar Pharma Private Limited capacity to increase from 0.5 Bn to 1.2 Bn units at an estimated cost of ₹20.00 Cr. - Ratnatris Pharmaceuticals to add a new Prefilled Syringe line (2.7 Mn units) at ₹5.00 Cr. - All expansions to be completed by March 2027.

- Senores Pharmaceuticals Limited submitted the outcome of the Board Meeting held on October 29, 2026. - Routine corporate filing detailing board decisions.

Concall Schedule Concall Date: October 29, 2026 Concall Time: 04:00 P.M. IST

Concall Schedule Concall Date: October 29, 2026 Concall Time: 05:00 P.M. (IST)

Senores Pharmaceuticals Limited has issued a Notice of Postal Ballot dated October 13, 2026, to seek shareholder approval via remote e-voting for two special resolutions: - Re-appointment of Mr. Swapnil Jatinbhai Shah as Managing Director for a 3-year term from October 15, 2026, to October 14, 2029. - Re-appointment of Mr. Chetan Bipinchandra Shah as Whole Time Director for a 3-year term from November 10, 2026, to November 09, 2029. - Remote e-voting period: October 19, 2026 (9:00 AM) to November 17, 2026 (5:00 PM). - Cut-off date for eligibility: October 09, 2026.

- Re-appointment of Mr. Swapnil Jatinbhai Shah as Managing Director for 3 years effective October 15, 2026. - Re-appointment of Mr. Chetan Bipinchandra Shah as Whole-Time Director for 3 years effective November 10, 2026. - Both re-appointments are subject to shareholder approval via postal ballot.

- Re-appointment of Mr. Swapnil Jatinbhai Shah as Managing Director for a period of 3 consecutive years effective October 15, 2026. - Re-appointment of Mr. Chetan Bipinchandra Shah as Whole Time Director for a period of 3 consecutive years effective November 10, 2026. - Both re-appointments are subject to shareholder approval via postal ballot.

- Approved re-appointment of Mr. Swapnil Jatinbhai Shah as Managing Director for 3 consecutive years effective October 15, 2026. - Approved re-appointment of Mr. Chetan Bipinchandra Shah as Whole-Time Director for 3 consecutive years effective November 10, 2026. - Both re-appointments are subject to shareholder approval via postal ballot.

- Trading window for designated persons will close from October 01, 2026. - Closure remains until 48 hours after the declaration of Q2/H1 FY27 un-audited financial results. - The date of the Board Meeting to approve financial results will be intimated separately.

- Senores Pharmaceuticals Limited responded to a clarification request from the stock exchanges regarding movement in volume. - The company confirmed compliance with SEBI (LODR) Regulations and stated there is no undisclosed price-sensitive information or impending corporate action.

- Senores Pharmaceuticals' subsidiary, Apnar Pharma Private Limited, successfully completed a USFDA inspection at its Vadodara manufacturing facility. - The inspection, conducted from September 07-11, 2026, had one minor procedural and no GMP-related observation.

- Concall Schedule - Concall Date: 02nd September 2026 - Concall Time: 11:00 AM (IST) Onwards - Hosted by: Elara Capital - Mode of Meeting: Physical at Mumbai

- Board meeting held on August 26, 2026. - Appointed Mrs. Shilpa Sharma as Company Secretary & Compliance Officer. - Appointed Mr. Viranchi Arvindbhai Shah as Non-Executive Additional Director (Independent Director). - Approved the Employee Stock Option Scheme 2026. - Approved incorporation of a Wholly Owned Subsidiary in Mexico and a Subsidiary in Canada for international expansion.

- The Board of Directors approved the appointment of Mrs. Shilpa Sharma as Company Secretary and Compliance Officer (KMP) w.e.f. August 26, 2026. - Approved the appointment of Mr. Viranchi Arvindbhai Shah as a Non-Executive Additional Director (Independent Director) w.e.f. August 26, 2026. - Approved the Senores Pharmaceuticals Employee Stock Option Scheme 2026, which covers 472,000 employee stock options (1% of existing equity on a fully diluted basis). - Approved the incorporation of a Wholly Owned Subsidiary (WOS) in Mexico (100% owned) for pharmaceutical product supply and distribution in Mexican and international markets. - Approved the incorporation of a Subsidiary Company in Canada (51% or more shareholding) for pharmaceutical product supply and distribution in the Canadian market.

- Board of Directors approved the appointment of Mrs. Shilpa Sharma as Company Secretary and Compliance Officer (KMP) w.e.f. August 26, 2026. - Board approved the appointment of Mr. Viranchi Arvindbhai Shah as Non-Executive Additional Director (Independent Director) w.e.f. August 26, 2026. - Approval for Senores Pharmaceuticals Employee Stock Option Scheme 2026 (ESOS 2026), covering 472,000 options (1% of existing equity). - Approved incorporation of a Wholly Owned Subsidiary (WOS) in Mexico for business and strategic objectives in Mexican and international markets. - Approved incorporation of a Subsidiary Company in Canada for business and strategic objectives in Canadian and international markets.

- The Board approved the appointment of Mrs. Shilpa Sharma as Company Secretary & Compliance Officer and Mr. Viranchi Arvindbhai Shah as a Non-Executive Additional (Independent) Director, effective August 26, 2026. - Approved the adoption of the Senores Pharmaceuticals Employee Stock Option Scheme 2026. - Approved the incorporation of a Wholly Owned Subsidiary in Mexico and a Subsidiary Company in Canada for international market expansion.

- Appointments: Mrs. Shilpa Sharma as Company Secretary & Compliance Officer and Mr. Viranchi Arvindbhai Shah as Non-Executive Additional (Independent) Director were approved. - ESOP: The Senores Pharmaceuticals Employee Stock Option Scheme 2026 was approved for 4,72,000 employee stock options. - Expansion: Approved the incorporation of a Wholly Owned Subsidiary in Mexico and a Subsidiary Company in Canada for market expansion.

- On August 26, 2026, the Board appointed Mrs. Shilpa Sharma as Company Secretary and Mr. Viranchi Arvindbhai Shah as Independent Director. - Approved Employee Stock Option Scheme 2026. - The Board also approved incorporating Wholly-Owned Subsidiaries in Mexico and Canada for strategic market expansion.

- Board approved the appointment of Mrs. Shilpa Sharma as Company Secretary & Compliance Officer (KMP) w.e.f. August 26, 2026. - Board approved the appointment of Mr. Viranchi Arvindbhai Shah as Non-Executive Additional Director (Independent Director) w.e.f. August 26, 2026. - Approved the Senores Pharmaceuticals Employee Stock Option Scheme 2026, encompassing 4,72,000 employee stock options. - Approved the proposed incorporation of a Wholly Owned Subsidiary in Mexico for pharmaceutical product supply and distribution, with 100% ownership. - Approved the proposed incorporation of a Subsidiary Company in Canada for pharmaceutical product supply and distribution, with 51% or more shareholding.

- Senores Pharmaceuticals Limited issued a Corporate Guarantee of INR 62 Crores on August 24, 2026. - The guarantee is for credit facilities availed by its subsidiary, Apnar Pharma Private Limited, from ICICI Bank Limited. - The transaction is at arm's length and is disclosed as a Contingent Liability with no other immediate impact on the Company.

- Analyst / Institutional Investor Meetings Schedule - Meeting Date: 25th August 2026 - Meeting Time: 11:00 AM (IST) Onwards - Hosted by: Antique Stock Broking - Mode: Physical at Mumbai

- Senores Pharmaceuticals Limited shareholders passed all resolutions via Postal Ballot, which concluded on August 03, 2026. - This includes approval for Material Related Party Transactions, enhancement of loan/guarantee/security limits, and variation in IPO proceeds utilization. - All 8 resolutions passed with requisite majority.

- FY27 revenue growth guidance of 30-40% YoY and PAT growth guidance of 50-60% YoY, with a similar trajectory expected thereafter. - Long-term revenue target of ₹2,500-₹3,000 crores in 3-4 years. - FY27 Capex plan of ₹100-120 crores for capacity expansion in oral solids and starting an injectable pilot plant, with FY28 run rate of ₹60-75 crores. - Strategic focus on expanding ANDA portfolio (currently 58 approved, 23 commercialized, 35 more in 18-20 months), ramping up Apnar facility utilization (80-90%), and pursuing European PIC/S approval for Chhatral facility by Q2/Q3. - New subsidiaries Zoraya and Amerisyn expected to commence operations around September/October this year. - Emerging market EBITDA margin expected to be 18-20% on a full-year basis, aiming to sustain overall margin profile of 30%+ as a minimum.

- Audio recording of the Earnings Conference Call held on July 27, 2026, for the quarter ended June 30, 2026, is now available on the company's website (https://senorespharma.com/investor-meet/). - No Unpublished Price Sensitive Information was shared during the call.

- Consolidated Revenue ₹180 Crs vs ₹132.6 Crs (▲36% YoY) - EBITDA ₹54 Crs vs ₹28.9 Crs (▲87% YoY) - PAT ₹31 Crs vs ₹19.9 Crs (▲56% YoY) - EBITDA Margin ~30.0% vs ~21.8% (▲800bps)

- Consolidated Revenue ₹180.21Cr vs ₹132.56Cr (▲36% YoY) - EBITDA ₹56.57Cr vs ₹37.52Cr (▲51% YoY) - PAT ₹30.45Cr vs ₹21.18Cr (▲44% YoY) - EBITDA Margin 31.39% vs 28.30% (▲309bps) - Board approved the appointment of Ms. Anjali Shah as Assistant Vice President-Finance and Senior Management Personnel (SMP) with effect from July 27, 2026.

- Consolidated Revenue ₹180.21 Cr vs ₹132.56 Cr (▲35.94% YoY) - EBITDA ₹53.76 Cr vs ₹28.73 Cr (▲87.12% YoY) - PAT ₹30.45 Cr vs ₹21.18 Cr (▲43.77% YoY) - EBITDA Margin 29.83% vs 21.67% (▲816bps)

- Consolidated Revenue ₹180.21Cr vs ₹132.56Cr (▲36% YoY) - EBITDA ₹53.76Cr vs ₹28.73Cr (▲87% YoY) - PAT ₹30.45Cr vs ₹21.18Cr (▲44% YoY) - EBITDA Margin 29.83% vs 21.67% (▲816bps) - The Board approved the appointment of Ms. Anjali Shah as Assistant Vice President-Finance (Senior Management Personnel) with effect from July 27, 2026.